Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 2
2012 1
2014 1
2016 2
2017 1
2018 1
2019 3
2020 4
2021 4
2022 1
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
[Tracheobronchitis as an extraintestinal manifestation of Crohn's disease].
Sakemi R, So S, Morimitsu Y, Noda T, Ohtsu K, Karashima Y, Imamura K, Terabe H, Chojin Y, Kato T. Sakemi R, et al. Nihon Shokakibyo Gakkai Zasshi. 2017;114(12):2125-2133. doi: 10.11405/nisshoshi.114.2125. Nihon Shokakibyo Gakkai Zasshi. 2017. PMID: 29213023 Review. Japanese.
Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study.
Nakase H, Wagatsuma K, Kobayashi T, Matsumoto T, Esaki M, Watanabe K, Kunisaki R, Takeda T, Arai K, Ibuka T, Ishikawa D, Matsuno Y, Sakuraba H, Ueno N, Yokoyama K, Saruta M, Hokari R, Yokoyama J, Tamano S, Nojima M, Hisamatsu T; MEFV-IBDU Group. Nakase H, et al. EBioMedicine. 2024 Dec;110:105454. doi: 10.1016/j.ebiom.2024.105454. Epub 2024 Nov 19. EBioMedicine. 2024. PMID: 39566399 Free PMC article.
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Kobayashi T, et al. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437. doi: 10.1016/S2468-1253(21)00062-5. Epub 2021 Apr 20. Lancet Gastroenterol Hepatol. 2021. PMID: 33887262 Clinical Trial.
Altered serum profile of the interleukin-22 system in inflammatory bowel disease.
Sakemi R, Mitsuyama K, Morita M, Yoshioka S, Kuwaki K, Tokuyasu H, Fukunaga S, Mori A, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Mizoguchi A, Sou S, Torimura T. Sakemi R, et al. Cytokine. 2020 Dec;136:155264. doi: 10.1016/j.cyto.2020.155264. Epub 2020 Sep 10. Cytokine. 2020. PMID: 32920320
Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K, Yamauchi R, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Tsuruta O, Torimura T. Mori A, et al. Among authors: sakemi r. Kurume Med J. 2021 Dec 15;66(4):209-215. doi: 10.2739/kurumemedj.MS664009. Epub 2021 Oct 25. Kurume Med J. 2021. PMID: 34690210 Free article.
Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease.
Yoshida A, Kamata N, Yamada A, Yokoyama Y, Omori T, Fujii T, Hayashi R, Kinjo T, Matsui A, Fukata N, Takahashi S, Sakemi R, Ogata N, Ashizuka S, Bamba S, Ooi M, Kanmura S, Endo K, Yoshino T, Tanaka H, Morizane T, Shinzaki S, Kobayashi T. Yoshida A, et al. Among authors: sakemi r. Inflamm Intest Dis. 2019 Apr;3(4):167-172. doi: 10.1159/000495035. Epub 2019 Feb 6. Inflamm Intest Dis. 2019. PMID: 31111032 Free PMC article.
22 results